Facebook
Twitter
LinkedIn
ForwardDecoding CIDP Strategies to Overcome Common Diagnostic and Therapeutic Pitfalls
Due to the unique educational design of this course, the content must be viewed and completed on the myCME platform.
Program Description
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder whose treatment landscape has recently expanded with the introduction of novel therapies with unique mechanisms of action and routes of administration. Despite these advances, CIDP is prone to misdiagnosis. Join esteemed CIDP experts Dr. Nicholas Silvestri, Dr. Jeffrey Allen, and Dr. Christyn Edmundson as they teach you how to avoid common diagnostic pitfalls by optimizing nerve conduction studies and accurately interpreting cerebrospinal fluid protein with updated criteria. Gain expert insights into how best to integrate newly FDA-approved therapies into current CIDP treatment regimens while also exploring promising late-stage clinical developments in the field. After the presentation, test your knowledge in a patient simulation to practice optimal CIDP management strategies.
Target Audience
The target audience for this initiative includes neuromuscular specialists, general neurologists, nurse practitioners, physician assistants, and other healthcare professionals involved in the diagnosis and long-term management of patients with CIDP.
Learning Objectives
Upon completion of the educational activity, participants should be able to:
- Formulate streamlined, evidence-based diagnostic strategies for chronic inflammatory demyelinating polyneuropathy (CIDP) that balance presentation (e.g., possible symptoms, atypical variants) and assessment (e.g., electrodiagnostics) components of the diagnostic criteria to ensure patients are not over- or misdiagnosed.
- Evaluate the relative risks and benefits of traditional and modern therapies to effectively individualize therapeutic regimens.
- Distinguish the mechanisms of action and evaluate clinical data for recently approved and emerging therapies in CIDP to determine their current and future roles in its management.
Nicholas J. Silvestri, MD, FAANProfessor of Neurology
Associate Dean for Student and Academic Affairs
University at Buffalo Jacobs School of Medicine and Biomedical Sciences
Buffalo, NY
Jeffrey Allen, MDProfessor of Neurology
University of Minnesota School of Medicine
Minneapolis, MN
Christyn Edmundson, MDThis activity is jointly provided by Medical Education Resources (MER) and Efficient LLC.
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Efficient LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Designation Statement
Medical Education Resources has been authorized by the American Academy of Physician Assistants (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME Credits. Physician Assistants should only claim credit commensurate with the extent of their participation.Disclosure of Relevant Financial Relationships
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies all financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company.
Staff Disclosures
Efficient LLC and Medical Education Resources' planners and managers have no financial relationships to disclose.
Faculty Disclosures
The program faculty reported the following relevant financial relationships that they have with commercial interests:
Dr. Silvestri discloses the following:
Consulting Fees: Alexion, Amgen, argenx, Immnovant, InhibRx, Janssen, and UCB
Speakers’ Bureau: Alexion, argenx, and UCB
Dr. Allen discloses the following:
Consulting Fees: Alexio, Alnylam, argenx, CSL Behring, Dianthus, Immmunovant, Grifols, Octapharma, and Takeda
Speakers’ Bureau: Alexion, Alnylam, argenx, and CSL Behring
Dr. Gwathmey discloses the following:
Consulting Fees: Alexion, argenX, and UCP
Speakers’ Bureau: Alexion, argenX, and UCP
Disclosure of Unlabeled Use/Disclaimer
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Efficient LLC and argenX. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
Commercial Support
This continuing education activity is supported by an educational grant from ArgenX.
Media
Internet